|
業務類別
|
Biotechnology |
|
業務概覽
|
Sensei Biotherapeutics Inc is a clinical-stage biotechnology company engaged in the development of therapies targeting cancer through multi-node inhibition of oncogenic pathways. The company's lead program, PIKTOR, is an investigational oral combination therapy designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway and is being evaluated for the treatment of endometrial and breast cancers. In addition, the company is advancing other pipeline programs targeting tumormetabolism and signaling pathways. |
| 公司地址
| 1405 Research Boulevard, Suite 125, Rockville, MD, USA, 20850 |
| 電話號碼
| +1 240 243-8000 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.senseibio.com |
| 員工數量
| 29 |
| Mr. Anand Kiran Parikh |
Director and Chief Operating Officer |
-- |
18/02/2026 |
| Mr. Christopher W Gerry |
President, Principal Executive Officer and General Counsel |
美元 398.18K |
16/04/2026 |
| Dr. Brian C. Stephenson, PhD |
Chief Financial Officer |
-- |
27/04/2026 |
| Mr. Josiah Craver |
Senior Vice President, Finance, Principal Financial Officer and Principal Accounting Officer |
美元 372.65K |
27/04/2026 |
|
|
| Ms. Saira Ramasastry |
Independent Director |
27/04/2026 |
| Dr. Karen H. Vousden, PhD |
Independent Director |
27/04/2026 |
| Mr. Kristian F. Humer |
Independent Director |
16/04/2026 |
| Mr. Bob Holmen |
Independent Director |
27/04/2026 |
| Mr. Anand Kiran Parikh |
Director and Chief Operating Officer |
18/02/2026 |
| Mr. Phillip B. Donenberg |
Director |
13/02/2026 |
| Mr. Thomas G. Ricks |
Independent Director |
16/04/2026 |
| Mr. Stephen M. Hahn |
Independent Director |
27/04/2026 |
|
|
|
|
